Article | Published:

Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin


Recent studies have suggested that the lipid-lowering agent simvastatin holds great promise as a cancer therapeutic; it inhibits the growth of multiple tumors, including triple-negative breast cancer. Doxorubicin- and simvastatin-induced cytotoxicity has been associated with the modulation of Ca2+ signaling, but the underlying mechanisms remain incompletely understood. Here we identify how Ca2+ signaling regulates the breast tumor cell response to doxorubicin and simvastatin. These two drugs inhibit cell survival while increasing apoptosis in two human breast cancer cell lines and five primary breast tumor specimens through the modulation of Ca2+ signaling. Signal transduction and functional studies revealed that both simvastatin and doxorubicin trigger persistent cytosolic Ca2+ release, thereby stimulating the proapoptotic BIM pathway and mitochondrial Ca2+ overload, which are responsible for metabolic dysfunction and apoptosis induction. Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. In addition, reduction of the Ca2+ signal by chelation or pharmacological inhibition significantly prevents drug-mediated anticancer signaling. Unexpectedly, a scratch-wound assay indicated that these two drugs induce rapid cell migration, while inhibiting cell invasion and colony formation in a Ca2+-dependent manner. Further, the in vivo data for MDA-MB-231 xenografts demonstrate that upon chelation of Ca2+, the ability of both drugs to reduce the tumor burden was significantly reduced via caspase-3 deactivation. Our results establish a calcium-based mechanism as crucial for executing the cell death process triggered by simvastatin and doxorubicin, and suggest that combining simvastatin with doxorubicin may be an effective regimen for the treatment of breast cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22:547–56.

  2. 2.

    Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-Borojeni AA, Sahebkar A, et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther. 2017;24:189–93.

  3. 3.

    Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.

  4. 4.

    Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ. 2002;9:561–73.

  5. 5.

    Gajek A, Denel-Bobrowska M, Rogalska A, Bukowska B, Maszewski J, Marczak A. Early activation of apoptosis and caspase-independent cell death plays an important role in mediating the cytotoxic and genotoxic effects of WP 631 in ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16:8503–12.

  6. 6.

    Szwed M, Laroche-Clary A, Robert J, Jozwiak Z. Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation. Cell Oncol (Dordr). 2016;39:107–18.

  7. 7.

    Zhang HT, Wang WW, Ren LH, Zhao XX, Wang ZH, Zhuang DL, et al. The mTORC2/Akt/NFκB pathway-mediated activation of TRPC6 participates in adriamycin-induced podocyte apoptosis. Cell Physiol Biochem. 2016;40:1079–93.

  8. 8.

    Gao J, Chen T, Zhao D, Zheng J, Liu Z, Ginkgolide B. Exerts cardioprotective properties against doxorubicin-induced cardiotoxicity by regulating reactive oxygen species, Akt and calcium signaling pathways in vitro and in vivo. PLoS ONE. 2016;11:e0168219.

  9. 9.

    Huang X, Xu Y, Liu Y, Xie H, Wang J, Wu Z. Extracellular Ca(2+) selectively enhances adriamycin-induced cell death in human hepatoma cells. Curr Cancer Drug Targets. 2015;15:481–92.

  10. 10.

    Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8:1913–24.

  11. 11.

    Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.

  12. 12.

    Safwat S, Ishak RA, Hathout RM, Mortada ND. Statins anticancer targeted delivery systems: re-purposing an old molecule. J Pharm Pharmacol. 2017;69:613–24.

  13. 13.

    Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Brañes J, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2010;14:1180–93.

  14. 14.

    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66:8707–14.

  15. 15.

    Mortimer JE, Axelrod R, Zimbro K. Effect of statins on breast cancer incidence: findings from the Sentara Health Plan. Proc Am Soc Clin Oncol. 2003;22:93.

  16. 16.

    Wu QJ, Tu C, Li YY, Zhu J, Qian KQ, Li WJ, et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015;6:42988–3004.

  17. 17.

    Katz MS. Therapy Insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005;2:82–9.

  18. 18.

    Borahay MA, Kilic GS, Yallampalli C, Snyder RR, Hankins GD, Al-Hendy A, et al. Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells. J Biol Chem. 2014;289:35075–86.

  19. 19.

    Mattson MP, Chan SL. Calcium orchestrates apoptosis. Nat Cell Biol. 2003;5:1041–3.

  20. 20.

    Parekh AB. Store-operated CRAC channels: function in health and disease. Nat Rev Drug Discov. 2010;9:399–410.

  21. 21.

    Tanwar J, Motiani RK. Role of SOCE architects STIM and Orai proteins in Cell Death. Cell Calcium. 2017;69:19–27.

  22. 22.

    Liao Y, Plummer NW, George MD, Abramowitz J, Zhu MX, Birnbaumer L. A role for Orai in TRPC-mediated Ca2+entry suggests that a TRPC:Orai complex may mediate store and receptor operated Ca2+entry. Proc Natl Acad Sci USA. 2009;106:3202–6.

  23. 23.

    Motiani RK, Abdullaev IF, Trebak M. A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem. 2010;285:19173–83.

  24. 24.

    Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M, et al. Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines? Tumour Biol. 2014;35:8033–41.

  25. 25.

    Leung YM, Kwan CY. Current perspectives in the pharmacological studies of store-operated Ca2+entry blockers. Jpn J Pharmacol. 1999;81:253–8.

  26. 26.

    Cheng H, Wang S, Feng R. STIM1 plays an important role in TGF-β-induced suppression of breast cancer cell proliferation. Oncotarget. 2016;7:16866–78.

  27. 27.

    Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle. 2009;8:1168–75.

  28. 28.

    Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55.

  29. 29.

    Liu C, Ye Y, Zhou Q, Zhang R, Zhang H, Liu W, et al. Crosstalk between Ca2+signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis. Oncotarget. 2016;7:7534–49.

  30. 30.

    Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129:1337–49.

  31. 31.

    David L, Dulong V, Le Cerf D, Cazin L, Lamacz M, Vannier JP. Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater. 2008;4:256–63.

  32. 32.

    David L, Dulong V, Le Cerf D, Chauzy C, Norris V, Delpech B, et al. Reticulated hyaluronan hydrogels: a model for examining cancer cell invasion in 3D. Matrix Biol. 2004;23:183–93.

  33. 33.

    Marchi S, Pinton P. Alterations of calcium homeostasis in cancer cells. Curr Opin Pharmacol. 2016;29:1–6.

  34. 34.

    Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A. TRP channels: diagnostic markers and therapeutic targets for breast cancer? Trends Mol Med. 2013;19:117–24.

  35. 35.

    Shi J, Miralles F, Birnbaumer L, Large WA, Albert AP. Store-operated interactions between plasmalemmal STIM1 and TRPC1 proteins stimulate PLCβ1 to induce TRPC1 channel activation in vascular smooth muscle cells. J Physiol. 2017;595:1039–58.

  36. 36.

    Giorgi C, Bonora M, Sorrentino G, Missiroli S, Poletti F, Suski JM, et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+ -dependent manner. Proc Natl Acad Sci USA. 2015;112:1779–84.

  37. 37.

    Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol. 2012;13:566–78.

  38. 38.

    Zhang S, Chen Y, Wu X, Gao H, Ma R, Jiang C, et al. The pivotal role of Ca2+homeostasis in PBDE-47-induced neuronal apoptosis. Mol Neurobiol. 2016;53:7078–88.

  39. 39.

    Tiwari M, Prasad S, Shrivastav TG, Chaube SK. Calcium signaling during meiotic cell cycle regulation and apoptosis in mammalian oocytes. J Cell Physiol. 2017;232:976–81.

  40. 40.

    Vashisht A, Trebak M, Motiani RK. STIM and Orai proteins as novel targets for cancer therapy. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309:C457–69.

  41. 41.

    Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.

  42. 42.

    Li Y, Liu H, Huang YY, Pu LJ, Zhang XD, Jiang CC, et al. Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase. Int J Mol Med. 2013;31:1234–42.

  43. 43.

    Einbond LS, Wu HA, Sandu C, Ford M, Mighty J, Antonetti V, et al. Digitoxin enhances the growth inhibitory effects of thapsigargin and simvastatin on ER negative human breast cancer cells. Fitoterapia. 2016;109:146–54.

  44. 44.

    Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.

  45. 45.

    Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Oncotarget. 2015;6:27388–402.

  46. 46.

    Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22:6785–93.

  47. 47.

    Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA. 2004;101:15313–17.

  48. 48.

    Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia. 2009;23:1744–54.

  49. 49.

    Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett. 2017;14:6243–50.

  50. 50.

    Simon T, Coquerel B, Petit A, Kassim Y, Demange E, Le Cerf D, et al. Direct effect of bevacizumab on glioblastoma cell lines in vitro. Neuromolecular Med. 2014;16:752–71.

  51. 51.

    Abdoul-Azize S, Dubus I, Vannier JP. Improvement of dexamethasone sensitivity by chelation of intracellular Ca2+ in pediatric acute lymphoblastic leukemia cells through the prosurvival kinase ERK1/2 deactivation. Oncotarget. 2017;8:27339–52.

Download references


This work was supported by grants from the French Ministry of Higher Education and Research, and the Association Vie et Espoir. We thank members of the LIONS CLUB Les Andelys association for their support with equipment.

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Souleymane Abdoul-Azize.

Electronic supplementary material

Supp_Figure S1

Supp_Figure S2

Supp_Figure S3

Supp_Figure S4

Supp_Figure S5

Suppl. Tables and Figures legends

Suppl. Materials and Methods

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7